BusinessRaptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International CongressBy Nasdaq OMXAug 24, 2016, 11:30 AM UTC
BusinessProteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential for Genotype-Agnostic and Combination Therapies for People with Cystic FibrosisBy Nasdaq OMXMar 30, 2016, 6:08 PM UTC
BusinessProteostasis Therapeutics, Inc. Announces Scientific Presentations at 13th Annual European Cystic Fibrosis Society Basic Science ConferenceBy Nasdaq OMXMar 28, 2016, 11:30 AM UTC
BusinessRaptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority ReviewBy Nasdaq OMXMar 21, 2016, 8:05 PM UTC
BusinessRaptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled LevofloxacinBy Nasdaq OMXMar 16, 2016, 11:30 AM UTC
BusinessRaptor Pharmaceutical to Participate in International Rare Disease Week Through Multiple Patient Advocacy ActivitiesBy Nasdaq OMXFeb 29, 2016, 12:30 PM UTC
BusinessRaptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate UpdateBy Nasdaq OMXFeb 25, 2016, 9:05 PM UTC
